Mei Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mei Yu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Xiaolong Li
Department of Oral and Maxillofacial Surgery, Guanghua School of Stomatology, Hospital of Stomatology and Guangdong Provincial Key Laboratory of Stomatology , SunYat-sen University , Guangzhou 510055 , China
2 shared publicationsYan Zhang
Laboratory of Cancer and Stem Cell Biology, Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences , Sun Yat-sen University, Guangzhou Higher Education Mega Center , Guangzhou 510006 , China
2 shared publications- A. Wang
Department of Oral and Maxillofacial Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication - Anxun Wang
Department of Oral and Maxillofacial Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication Guiyun Wu
Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publicationH. Wang
Department of Oral and Maxillofacial Surgery, Guangzhou Women and Children's Medical Center, Guangzhou, China
1 shared publication
Latest Publications
- 1 May 2020
- Published by Elsevier in British Journal of Oral and Maxillofacial Surgery
- Vol. 58 (4) , 437-442
Identification of a potential target for treatment of squamous cell carcinoma of the tongue: follistatin
- 1 May 2020
- Published by Elsevier in British Journal of Oral and Maxillofacial Surgery
- Vol. 58 (4) , 437-442
Identification of a potential target for treatment of squamous cell carcinoma of the tongue: follistatin
- 1 February 2020
- Published by Elsevier in Archives of Oral Biology
- Vol. 110, 104587
Bioinformatic screening and experimental analysis identify SFRP1 as a prognostic biomarker for tongue squamous cell carcinomas
- 1 February 2020
- Published by Elsevier in Archives of Oral Biology
- Vol. 110, 104587
Bioinformatic screening and experimental analysis identify SFRP1 as a prognostic biomarker for tongue squamous cell carcinomas
- 21 December 2018
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 11 (2) , 2448-2458
New Cell-Penetrating Peptide (KRP) with Multiple Physicochemical Properties Endows Doxorubicin with Tumor Targeting and Improves Its Therapeutic Index
Cell penetrating peptides (CPPs) are considered as promising drug carriers in virtue of their potent cell penetrating capacity. However, lack of targetability still represents a bottleneck for their systemic administration. Here we synthesized a lysine-rich CPP named KRP and developed a tumor targeted drug delivery system (DDS) by linking KRP and doxorubicin(DOX)with stable covalent bonds (thioether bond and amide bond). Through in vitro and in vivo tests, we confirmed that the multiple physicochemical properties of KRP endow KRP-DOX with multiple synergistic functions including good biocompatibility and biodistribution, selective accumulation in tumor tissues, inclination to remain in tumor tissues and be internalization by tumor cells; Stable covalent bonds prevent free DOX releasing from KRP-DOX in blood stream, thus shielding the toxic effect of DOX on normal tissues and achieving the majority DOX delivery into tumor cells by KRP; lysosome escape ability ensures that KRP-DOX can exert tumor killing effect after entering tumor cells. In addition, the simple design of KRP-DOX, i.e. the simple chemical composition and modification reduce the risk of immunogenicity and metabolites toxicity. Our study provides a simple, safe and efficient platform for tumor targeted DDS.
- 21 December 2018
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 11 (2) , 2448-2458
New Cell-Penetrating Peptide (KRP) with Multiple Physicochemical Properties Endows Doxorubicin with Tumor Targeting and Improves Its Therapeutic Index
Cell penetrating peptides (CPPs) are considered as promising drug carriers in virtue of their potent cell penetrating capacity. However, lack of targetability still represents a bottleneck for their systemic administration. Here we synthesized a lysine-rich CPP named KRP and developed a tumor targeted drug delivery system (DDS) by linking KRP and doxorubicin(DOX)with stable covalent bonds (thioether bond and amide bond). Through in vitro and in vivo tests, we confirmed that the multiple physicochemical properties of KRP endow KRP-DOX with multiple synergistic functions including good biocompatibility and biodistribution, selective accumulation in tumor tissues, inclination to remain in tumor tissues and be internalization by tumor cells; Stable covalent bonds prevent free DOX releasing from KRP-DOX in blood stream, thus shielding the toxic effect of DOX on normal tissues and achieving the majority DOX delivery into tumor cells by KRP; lysosome escape ability ensures that KRP-DOX can exert tumor killing effect after entering tumor cells. In addition, the simple design of KRP-DOX, i.e. the simple chemical composition and modification reduce the risk of immunogenicity and metabolites toxicity. Our study provides a simple, safe and efficient platform for tumor targeted DDS.